Syntegon Pharmatag 2025: enabling collaborative success

Mit mehr als 350 Teilnehmenden aus aller Welt verzeichnete die 10. Ausgabe des Pharmatags in Crailsheim einen Besucherrekord. / With more than 350 participants from all over the world, the 10th edition of Pharmatag in Crailsheim set a new visitor record.

„Eine enge Zusammenarbeit zwischen Kunden und Technologieanbietern ist wichtiger denn je“, betonte Torsten Türling, CEO der Syntegon-Gruppe, in seiner Eröffnungsrede. / “Close collaboration between customers and technology providers is more important than ever,” said Torsten Türling, CEO of the Syntegon Group, in his opening speech.

– 10th edition of Pharmatag with record participation.
– World premiere of SynTiso: innovative line concept for liquid pharmaceutical filling.
– Program presents latest innovations and successful, collaborative partnerships.

On May 20 and 21, 2025, Syntegon, a leading strategic partner to the global pharmaceutical, biotech, and food industries, hosted the 10th edition of its industry-leading Pharmatag. A record number of more than 350 global customers, partners, innovators, and leaders accepted Syntegon’s invitation to join the event.

“Close collaboration between customers and technology providers is more important than ever – especially when developing mission-critical solutions for the pharmaceutical and biotech industries,” said Torsten Türling, CEO of the Syntegon Group. “The many successful examples shared at Pharmatag clearly demonstrate this. What truly sets Syntegon apart is our unwavering commitment to partnership.”

Enabling collaborative success

The program featured a wide range of the latest innovations, expert insights, and real-world success stories. Among the highlights were the keynote speeches by Brigitte Reutter-Haerle, VP Product Management at Vetter Pharma, and Christa Myers, Process Chemical Engineer at CRB. Both emphasized the importance of collaboration today to shape the future of the pharmaceutical industry.

Case studies presented by Siegfried Hameln, GennVax, Lek d.d., Stevanato Group, and Aspen demonstrated how co-creation is already delivering tangible results. In addition, a behind-the-scenes look at Syntegon’s production gave attendees the opportunity to explore innovative machine concepts and bespoke customer projects firsthand.

World premiere of innovative new line concept SynTiso

The world premiere of the innovative line concept SynTiso revealed at Pharmatag exemplifies Syntegon’s new strategy, which focuses on growth, operational excellence, and long-term value creation. This strategy aims to build better businesses through seamless processes, provide customers with access to the most innovative technologies, and lead the market through sustainable solutions that stand the test of time.

The SynTiso line concept for liquid pharmaceutical filling was developed in close collaboration with two partners from the pharmaceutical industry. SynTiso addresses the current challenges faced by pharmaceutical manufacturers, who require high availability and full automation as well as maximum product yield and minimal operator intervention. “Together with our customers, we will revolutionize liquid filling,” says Stephan März, Executive VP Pharma Liquid at Syntegon.